XML 46 R29.htm IDEA: XBRL DOCUMENT v3.22.1
Long-Term Investments (Tables)
 3 Months Ended 12 Months Ended
Mar. 31, 2022
Dec. 31, 2021
Long Term Investment [Abstract]    
Schedule of ownership percentages of investee
   Ownership percentage    
   March 31,   December 31,   Accounting
Name of related party  2022   2021   treatments
Braingenesis Biotechnology Co., Ltd.   0.17%   0.17%  Cost Method
Genepharm Biotech Corporation   0.70%   0.70%  Cost Method
BioHopeKing Corporation   5.90%   5.90%  Cost Method
BioFirst Corporation   15.99%   15.99%  Equity Method
Rgene Corporation   31.62%   31.62%  Equity Method

 
    Ownership percentage      
    December 31,   December 31,   Accounting  
Name of related party   2021   2020   treatments  
Braingenesis Biotechnology Co., Ltd.   0.17%   0.17%   Cost Method  
Genepharm Biotech Corporation   0.70%   0.70%   Cost Method  
BioHopeKing Corporation   5.90%   5.90%   Cost Method  
BioFirst Corporation   15.99%   15.99%   Equity Method  
Rgene Corporation   31.62%   31.62%   Equity Method  

 
Schedule of extent the investee relies
Name of related party  The extent the investee relies on the Company for its business
Braingenesis Biotechnology Co., Ltd.  No specific business relationship
Genepharm Biotech Corporation  No specific business relationship
BioHopeKing Corporation  Collaborating with the Company to develop and commercialize drugs
BioFirst Corporation  Collaborating with the Company to develop and commercialize drugs
Rgene Corporation  Collaborating with the Company to develop and commercialize drugs

  
Name of related party   The extent the investee relies on the Company for its business
Braingenesis Biotechnology Co., Ltd.   No specific business relationship
Genepharm Biotech Corporation   No specific business relationship
BioHopeKing Corporation   Collaborating with the Company to develop and commercialize drugs
BioFirst Corporation   Loaned from the investee and provides research and development support service
Rgene Corporation   Collaborating with the Company to develop and commercialize drugs

 
Schedule of long-term investment
   March 31,
2022		   December 31,
2021		 
   (Unaudited)     
Non-marketable Cost Method Investments, net          
Braingenesis Biotechnology Co., Ltd.  $7,698   $7,941 
Genepharm Biotech Corporation   23,503    24,244 
BioHopeKing Corporation   873,053    900,570 
Sub total   904,254    932,755 
Equity Method Investments, net          
BioFirst Corporation   
-
    
-
 
Rgene Corporation   
-
    
-
 
Total  $904,254   $932,755 

  
    December 31,
2021		     December 31,
2020		  
Non-marketable Cost Method Investments, net                
Braingenesis Biotechnology Co., Ltd.   $ 7,941     $ 7,853  
Genepharm Biotech Corporation     24,244       23,974  
BioHopeKing Corporation     900,570       890,564  
Sub total     932,755       922,391  
Equity Method Investments, net                
BioFirst Corporation    
-
       268,336  
Rgene Corporation    
-
      
-
  
Total   $ 932,755     $ 1,190,727  

 
Schedule of balance sheets
   March 31,
2022		   December 31,
2021		 
   (Unaudited)     
Current Assets  $2,147,097   $2,205,669 
Non-current Assets   812,865    959,454 
Current Liabilities   3,237,623    2,909,703 
Non-current Liabilities   17,741    32,522 
Stockholders’ Equity   (295,402)   222,898 

 

   March 31,
2022		   December 31,
2021		 
   (Unaudited)     
Current Assets  $221,169   $73,452 
Noncurrent Assets   355,420    374,423 
Current Liabilities   2,164,077    1,934,786 
Noncurrent Liabilities   
-
    
-
 
Shareholders’ Deficit   (1,587,488)   (1,486,911)

 
    December 31,
2021		     December 31,
2020		  
Current Assets   $ 2,205,669     $ 1,299,822  
Noncurrent Assets     959,454       2,540,041  
Current Liabilities     2,909,703       1,986,340  
Noncurrent Liabilities     32,522       73,197  
Stockholders’ Equity     222,898       1,780,326  

 

    December 31,
2021		     December 31,
2020		  
Current Assets   $ 73,452     $ 123,958  
Noncurrent Assets     374,423       412,342  
Current Liabilities     1,934,786       1,392,756  
Noncurrent Liabilities     -       38,953  
Shareholders’ Deficit     (1,486,911 )     (895,409 )

 
Schedule of statements of operation
   Three Months Ended
March 31,		 
   2022   2021 
   (Unaudited) 
Net sales  $8,808   $12,339 
Gross profit   6,133    7,080 
Net loss   (498,940)   (220,855)
Share of losses from investments accounted for using the equity method   -    (47,791)

 

   Three Months Ended
March 31,		 
   2022   2021 
   (Unaudited) 
Net sales  $
-
   $- 
Gross Profit   
-
    - 
Net loss   (149,480)   (95,395)
Share of loss from investments accounted for using the equity method   
-
    
-
 

 
    Year Ended
December 31,		  
    2021     2020  
Net sales   $ 26,693     $ 257,235  
Gross profit     8,348       10,121  
Net loss     (2,276,892 )     (5,401,074 )
Share of losses from investments accounted for using the equity method     (269,844 )     (1,168,733 )

 

    Year Ended
December 31,		  
    2021     2020  
Net sales   $
-
     $ 16,595  
Gross Profit    
-
       (335,735 )
Net loss     (576,514 )     (641,636 )
Share of loss from investments accounted for using the equity method    
-
      
-
  

 
Schedule of equity investments
   Three Months Ended
March 31,		 
   2022   2021 
   (Unaudited) 
Share of equity method investee losses  $
-
   $(47,791)
    Year Ended
December 31,		  
    2021     2020  
Share of equity method investee losses   $ (269,844 )   $ (1,168,733 )